Mercer Global Advisors
ORMP icon

Mercer Global Advisors’s Oramed Pharmaceuticals ORMP Stock Holding History

Mercer Global Advisors’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.5M Buy
+1,910,540
New +$6.48M 0.01% 657

Other funds holding ORMP

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
AF
Aquamarine Financial George Town $1.37B AUM
GIA
Gem Investment Advisors Teaneck, New Jersey $102M AUM
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $25B AUM 18.87% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $5.76B AUM 24.57% 1-Year Est. Return

Mercer Global Advisors's ORMP Position: Q1 2026 in Review

Mercer Global Advisors opened a new position in Oramed Pharmaceuticals (ORMP) in Q1 2026: 1,910,540 shares worth $6.5M. The stake represents 0.01% of the portfolio and ranks #657 among its holdings.

64 funds tracked by Wall St. Rank hold ORMP as of Q1 2026.

  • Mercer Global Advisors held 1,910,540 shares of Oramed Pharmaceuticals worth $6.5M as of Q1 2026.
  • Oramed Pharmaceuticals was a new Mercer Global Advisors position in Q1 2026.
  • Oramed Pharmaceuticals made up 0.01% of Mercer Global Advisors's portfolio in Q1 2026, its #657 holding.
  • 64 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2026.

Based on Mercer Global Advisors's 13F filing for Q1 2026, filed 15 May 2026.